BioGaia has signed an exclusive distributor agreement with Phillips Pharma Group
for the rights to sell BioGaia ProTectis drops, tablets and Oral Rehydration
Solution in Kenya, Nigeria and Ghana. The products will be sold under the
BioGaia brand and the launch is planned to start in Kenya in 2016.
Phillips Pharma Group was established in Kenya in 1991, focusing on importing,
marketing and distributing pharmaceuticals. Today the company has more than
1,000 employees and is present in seven countries around Africa – Kenya,
Nigeria, Tanzania, Zambia, Uganda, Rwanda and Ghana – covering 350 million
people or 35 percent of Africa’s population. The Phillips Group operations have
been extended with subsidiaries specialized in surgical products, medical
devices and diagnostics. Among the partners are important international
pharmaceutical companies such as Novartis, Abbott, Sandoz and Menarini.
“Phillips Pharma Group, believes in a long term partnership with BioGaia and is
committed to market and position its probiotics as an innovative and premium
brand in the market. The experience we have working close to doctors and
specialists will allow us to achieve BioGaia’s expectations and goals”, says
Niraj Doshi, CEO, Phillips Pharma Group Ltd.
”I am very happy that we have signed an agreement that gives BioGaia access to
Central and Eastern Africa, a market with large potential for our products.
Phillips Pharma Group is a strong and reliable partner with local presence in
several important markets and I look forward to a fruitful collaboration”, says
Axel Sjöblad, Managing Director, BioGaia.
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-
enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the Nasdaq OMX Nordic Exchange Stockholm.
BioGaia AB Box 3242. SE-103 64 STOCKHOLM Street address: Kungsbroplan 3A,
Stockholm Telephone: +46 8 555 293 00, Corp. identity no. 556380
Last updated on: 15/09/2016